Business Wire

Tanner Pharma Group Announces LEUKINE EMERGENCY ACCESS PROGRAM (LEAP) to Provide Increased International Access to LEUKINE® (sargramostim)

Share

Tanner Pharma Group today announced they are expanding their program by which the company provides access to LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.

On March 23, 2020, Partner Therapeutics announced that Leukine® is being assessed in the SARPAC trial ( sar gramostim in p atients with a cute hypoxic respiratory failure due to C OVID-19 – EudraCT #2020-001254-22) at University Hospital Ghent, Belgium to treat patients with respiratory illness associated with COVID-19.

“The collaboration we have had with Tanner Pharma Group has given us a regulatory-compliant pathway to make LEUKINE available in international markets,” said Bob Mulroy, CEO of Partner Therapeutics. “The expansion of this partnership makes Tanner our designated program manager and creates a shared objective to more effectively provide access to more patients in need.”

If a patient is located in a country where Leukine is not available commercially and has a life-threatening illness whereby survival could potentially be prolonged in a clinically meaningful way, physicians may be able to have Leukine imported for their patients through named patient supply via the LEUKINE EMERGENCY ACCESS PROGRAM (LEAP) managed by Tanner.

“Leukine has been an important part of the treatment regimen for various diseases over the past thirty years; now, there is an even greater possible need as demonstrated by initiation of the clinical trial in Belgium,” said Banks Bourne, CEO of Tanner Pharma Group. “Tanner has been managing this access program for Leukine since May of 2018 and we are ready for this new, very important phase. Our team is incredibly honored to be trusted with the expansion of this collaboration, and we are mobilized to help patients around the world to make a positive impact.”

For more information about this program or to request access to LEUKINE®:

Telephone: +1 704 643 8989

Email: leukine@tannerpharma.com

About LEUKINE® (sargramostim)

Leukine® is a yeast-derived recombinant humanized granulocyte-macrophage colony stimulating factor (rhuGM-CSF) and the only FDA approved GM-CSF. GM-CSF is an important leukocyte growth factor known to play a key role in hematopoiesis, epithelial repair, and augmentation of innate host defense by effecting the growth and maturation of multiple cell lineages as well as the functional activities of these cells in antigen presentation and cell mediated immunity.

About Tanner Pharma Group

Tanner Pharma Group partners with biopharmaceutical companies to provide turn-key commercialization solutions to increase patient access to medicines around the world. With an unparalleled blend of local market knowledge, international supply chain expertise across more than 130 countries, and high regulatory compliance and quality standards, it provides tailored solutions to biopharmaceutical companies outside their core markets of focus. For more information, visit www.tannerpharma.com.

Contact information

Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Piper Sandler Completes Acquisition of Preeminent Chemicals Investment Bank, The Valence Group4.4.2020 00:13:00 EESTPress release

Piper Sandler Companies (NYSE: PIPR), a leading investment bank and institutional securities firm, today announced it has completed its acquisition of The Valence Group, a premier international investment bank specializing in the chemicals, materials and related sectors. The Valence Group will operate as Piper Sandler’s new chemicals & materials group, adding yet another industry-leading advisory practice to the Piper Sandler platform. In addition, Peter Hall, one of the founders of The Valence Group, will now lead Piper Sandler’s expansion of investment banking in Europe. Piper Sandler was advised by its wholly owned subsidiary, Piper Sandler & Co., and was represented by Sullivan & Cromwell LLP. Houlihan Lokey served as financial advisor and Dentons as legal advisor to The Valence Group in connection with the transaction. About Piper Sandler Piper Sandler is a leading investment bank and institutional securities firm driven to help clients Realize the Power of Partnership®. Through a

BitHull Overtakes ASIC Market with New FPGA Miners3.4.2020 20:38:00 EESTPress release

BitHull S.A. ( www.BitHull.com ) is pleased to announce the launch of its two new crypto miners BH Miner and BH Miners Box. These miners have been built around Field Programmable Gate Array or FPGA mining technology, the latest breakthrough in crypto mining. FPGA mining makes use of the new generation of FPGA chips capable of delivering high hash rate power at low power consumption. Owing to its outstanding features, FPGA mining is expected to overtake ASIC mining very soon. BH Miner and BH Miners Box are multi-algorithm miners capable of mining bitcoin, litecoin, ethereum, and monero. BH Miners Box is a box combining 6 BH Miner units connected to each other. Mentioned below are the key features of the two miners. BH Miner Hash Rates: Bitcoin: 360 TH/s, Litecoin: 60 GH/s, Ethereum: 15 GH/s, and Monero: 3 MH/s BH Miners Box: Bitcoin: 2160 TH/s, Litecoin: 360 GH/s, Ethereum: 90 GH/s, and Monero: 18 MH/s Power consumption: 550W and 550W x6 for BH Miner and BH Miners Box respectively The o

Celltrion’s COVID-19 Antiviral Treatment Enters the Next Phase of Development3.4.2020 11:00:00 EESTPress release

Celltrion Group today announced its successful transition to the second phase of development for an antiviral treatment to fight the novel coronavirus (COVID-19) pandemic, following the completion of the first phase of securing 300 different types of antibodies that bind to the antigen last month. The library of antibodies was created using the blood of recovered patients in Korea. In cooperation with the Korea Centers for Disease Control and Prevention (KCDC), Celltrion will be screening the antibodies to find the ones most effective in neutralising SARS-CoV-2, the virus responsible for COVID-19. Celltrion anticipates the candidate screening for the therapeutic monoclonal antibody (mAb) will be complete by mid-April, sooner than originally expected. Ki-Sung Kwon, Head of R&D Unit at Celltrion said, “Once we have selected the one that most effectively neutralizes the COVID-19 virus among hundreds of the screened antibodies, we will roll out mass production of the therapeutic antibody t

Oracle Water System of MAK Leads Prevention of COVID-19 in Korea3.4.2020 08:18:00 EESTPress release

The ozone water produced by Oracle Water System was proved to be effective in preventing epidemics as it was used in Korea which is recognized as an exemplary country in addressing Coronavirus Disease-19 (COVID-19) drawing attention from the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005897/en/ The ozone water ‘Oracle Water’ produced by Oracle Water System was proved to be effective in preventing epidemics as it was used in Korea which is recognized as an exemplary country in addressing COVID-19 drawing attention from the world. ‘Oracle Water’ was begun to be used as sterilizing water in Daegu, Korea and demonstrated the remarkable effect of preventing COVID-19. The number of confirmed COVID-19 cases in the city decreased from 390 on March 7 when the sterilizing water was begun to be used to 297 cases on March 8, 190 cases on March 9 and to 32 cases on March 17, showing a reduction by 91.7%. Using plasma, Or

Strategic Investment of NXP in Kalray3.4.2020 00:52:00 EESTPress release

Kalray (Euronext Growth Paris : ALKAL – the “Company”), a pioneer in processors for new intelligent systems, today announces a strategic investment from NXP Semiconductors N.V. (NASDAQ: NXPI) for €8 million (approximately US$9 million), to enable the companies to develop together safe, reliable and scalable solutions for autonomous driving, combining NXP Automotive solutions and Kalray MPPA® (Massively Parallel Processor Array) Intelligent Processors. The investment will be carried out through the reserved issuance to NXP BV, a company of the NXP Group, of 503,461 ordinary shares without pre-emptive rights for the existing shareholders of the Company. Upon settlement-delivery of the new shares, the NXP Group will hold ca. 9.95% of Kalray’s share capital and voting rights. The settlement-delivery of the new shares is scheduled for April 7, 2020 and their admission to the Euronext Growth Paris multilateral trading system is scheduled for April 8, 2020. STRATEGIC NATURE OF THE TRANSACTION

Kalray: Information About Covid-193.4.2020 00:05:00 EESTPress release

Kalray (Paris:ALKAL) (Euronext Growth Paris : ALKAL), a pioneer in processors for new intelligent systems, is sharing the status on its activity and the continuation of its activity following the various health measures taken by the French government. The impact of Covid-19 epidemic on Kalray’s research and development activity, which is not too dependent on its suppliers, is expected to be limited and Kalray is hopeful it will be able to stick to its development roadmap. The development teams are fully operational thanks to telework, which was put in place as soon as the containment was announced in France on Monday March 16. The company does not use technical unemployment to date. However, the global health situation related to the Covid-19 epidemic and the containment measures implemented in many countries are likely to slow down business cycles, which could delay the deployment of some of company’s projects. At this stage, Kalray is currently assessing all the impacts of this crisi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom